Delcath Systems to Present at Lazard Capital Markets 6th Annual Healthcare Conference
November 16 2009 - 5:00AM
PR Newswire (US)
NEW YORK, Nov. 16 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, today announced that its President and CEO Eamonn P.
Hobbs and its CFO David A. McDonald will make a presentation to
investors at the Lazard Capital Markets 6th Annual Healthcare
Conference on Wednesday, November 18 at 2:45 p.m. Eastern Time at
The St. Regis Hotel in New York. Mr. Hobbs and Mr. McDonald will
review the company's business strategy and historic financial
results. A live webcast of the presentation will be available in
the investors section of the Company's web site at
http://www.delcath.com/. The webcast also will be archived and
accessible for 90 days. Delcath Systems, Inc. Delcath Systems, Inc.
is a medical device company specializing in cancer treatment. The
Company is testing a proprietary, patented drug delivery system for
the treatment of liver cancers. Delcath's novel drug delivery
platform is testing the delivery of ultra-high doses of anti-cancer
drugs to the liver while preventing these high doses of drug from
entering the patient's bloodstream. The Company is currently
enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company maintains a broad intellectual property portfolio on a
worldwide basis including the U.S., Europe, Asia and Canada. For
more information, please visit the Company's website at
http://www.delcath.com/. DATASOURCE: Delcath Systems, Inc. CONTACT:
Investor, Doug Sherk, Stacey Fisher, or Mike Pollock, all of EVC
Group, +1-415-896-6820; Media, Steve DiMattia of EVC Group,
+1-646-201-5445; all for Delcath Systems, Inc. Web Site:
http://www.delcath.com/
Copyright